Oral: Remarkably, BPC-157 retains bioactivity when administered orally
No adverse effects were noted in clinical trials (ulcerative colitis, phase II) [84,85], and in toxicological studies, a lethal dose (LD1) was not achieved (for review, see [11,12,13,14,24,25])
The following dosing protocol for healing with TB-500 is not supported by any studies published thus far, but it can serve as a starting point for researchers, who are advised to begin with still lower doses and titrate upward approaching this protocol: Daily Dose: 2mg, administered subcutaneously Frequency: Daily subcutaneous injections Study Duration: 15 days Notes: Researchers need three vials of TB-500 10mg to complete this protocol
Supplied in sealed laboratory vials, the material is intended for analytical investigation, assay development, and experimental applications in professional research environments where documentation and reproducibility are required
Clinical review